Table 7.
Investigator’s assessment of patient responses to mold-active triazole therapies at study end (FAS)
| Isavuconazole (n = 510) | Posaconazole (n = 540) | Voriconazole (n = 491) | Multiple/sequenced MAT therapies (n = 452) | Total (N = 1993) | |
|---|---|---|---|---|---|
| Clinical response assessment, n | 308 | 180 | 256 | 257 | 1001 |
| Resolution of all attributable signs/symptoms | 114 (37.0) | 68 (37.8) | 82 (32.0) | 92 (35.8) | 356 (35.6) |
| Resolution of some attributable signs/symptoms | 70 (22.7) | 27 (15.0) | 69 (27.0) | 69 (26.8) | 235 (23.5) |
| No resolution of any attributable signs/symptoms | 45 (14.6) | 25 (13.9) | 49 (19.1) | 54 (21.0) | 173 (17.3) |
| No attributable signs/symptoms | 65 (21.1) | 57 (31.7) | 43 (16.8) | 33 (12.8) | 198 (19.8) |
| Results not available/patient unevaluable | 14 (4.5) | 3 (1.7) | 13 (5.1) | 9 (3.5) | 39 (3.9) |
| Mycologic response assessment, n | 227 | 116 | 194 | 199 | 736 |
| Eradication | 48 (21.1) | 20 (17.2) | 28 (14.4) | 34 (17.1) | 130 (17.7) |
| Presumed eradication | 62 (27.3) | 29 (25.0) | 66 (34.0) | 49 (24.6) | 206 (28.0) |
| Persistence | 12 (5.3) | 9 (7.8) | 17 (8.8) | 25 (12.6) | 63 (8.6) |
| Presumed persistence | 18 (7.9) | 18 (15.5) | 23 (11.9) | 26 (13.1) | 85 (11.5) |
| Indeterminate | 7 (3.1) | 3 (2.6) | 5 (2.6) | 3 (1.5) | 18 (2.4) |
| Results not available/patient unevaluable | 80 (35.2) | 37 (31.9) | 55 (28.4) | 62 (31.2) | 234 (31.8) |
| Radiologic response assessment, n | 248 | 129 | 193 | 224 | 794 |
| ≥ 90% improvement | 60 (24.2) | 36 (27.9) | 40 (20.7) | 64 (28.6) | 200 (25.2) |
| ≥ 50 to < 90% improvement | 37 (14.9) | 21 (16.3) | 40 (20.7) | 34 (15.2) | 132 (16.6) |
| ≥ 25 to < 50% improvement | 26 (10.5) | 5 (3.9) | 14 (7.3) | 11 (4.9) | 56 (7.1) |
| < 25% improvement | 39 (15.7) | 28 (21.7) | 43 (22.3) | 57 (25.4) | 167 (21.0) |
| No signs on radiologic images | 33 (13.3) | 14 (10.9) | 30 (15.5) | 25 (11.2) | 102 (12.8) |
| Results not available/patient unevaluable | 53 (21.4) | 25 (19.4) | 26 (13.5) | 33 (14.7) | 137 (17.3) |
Data shown are n (%), unless otherwise indicated. Table shows actual number of patients with an assessment (n). Since treatment groups were not randomized and assessment results were not adjusted, any perceived differences between treatment groups could be due to other confounders and not treatment effects. Note that patients who received prophylaxis may have transitioned to treatment during the course of the study; for context, 816 and 1177 patients received treatment and prophylaxis, respectively, at study index/enrollment
FAS full analysis set